Evidence map›Paper›PMID 29895293›Full record

ReviewBMC surgery2018

Robotic treatment of oligometastatic kidney tumor with synchronous pancreatic metastasis: case report and review of the literature.

Andrea Boni, Giovanni Cochetti, Stefano Ascani, Michele Del Zingaro, Francesca Quadrini, Alessio Paladini, Diego Cocca, Ettore Mearini

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in BMC surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Andrea BoniDepartment of Surgical and Biomedical Sciences, Division of Urological, Andrological surgery and Minimally-invasive techniques, University of Perugia, Perugia, Italy.
Giovanni CochettiDepartment of Surgical and Biomedical Sciences, Division of Urological, Andrological surgery and Minimally-invasive techniques, University of Perugia, Perugia, Italy.
Stefano AscaniInstitute of Pathologic Anatomy, "Santa Maria" Hospital, Terni, Italy.
Michele Del ZingaroDepartment of Surgical and Biomedical Sciences, Division of Urological, Andrological surgery and Minimally-invasive techniques, University of Perugia, Perugia, Italy.
Francesca QuadriniDepartment of Surgical and Biomedical Sciences, Division of Urological, Andrological surgery and Minimally-invasive techniques, University of Perugia, Perugia, Italy.
Alessio PaladiniDepartment of Surgical and Biomedical Sciences, Division of Urological, Andrological surgery and Minimally-invasive techniques, University of Perugia, Perugia, Italy. alessiopaladini89@gmail.com.ORCID http://orcid.org/0000-0003-2680-3429
Diego CoccaDepartment of Surgical and Biomedical Sciences, Division of Urological, Andrological surgery and Minimally-invasive techniques, University of Perugia, Perugia, Italy.
Ettore MeariniDepartment of Surgical and Biomedical Sciences, Division of Urological, Andrological surgery and Minimally-invasive techniques, University of Perugia, Perugia, Italy.
University of Perugia · ITSanta Maria Nuova Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe management of metastatic Renal Cell Carcinoma (RCC) has changed dramatically in the last 20 years, and the role of surgery in the immunotherapy's era is under debate. Metastatic lesions interesting pancreas are infrequent, but those harbouring from RCC have an high incidence. If metachronous resections are not rare, synchronous resection of primary RCC and its pancreatic metastasis is uncommonly reported, and accounts for a bad prognosis. CASE PRESENTATION: We report the case of a 68 years old woman, who presented hematuria at hospital incoming, with radiological appearance of a 13 cm left renal mass, with a 2.5 cm single pancreatic tail metastasis. Work-up of staging ruled out other distant metastases, urothelial cancer and there was no evidence of inferior vena cava thrombosis. We choose a 5-port trans-peritoneal robotic approach using lazy right lateral decubitus. Synchronous robotic radical nephrectomy and spleen-sparing pancreatic resection was performed. The pancreatic mass was completely enucleated from pancreatic parenchyma using a latero-medial dissection. Peri-operative hemoglobine loss was 2.4 g/dL. Total operative time was 213 min. No post-operative complications were recorded and patient was discharged in 7th post-operative day. Histopathological examination showed a pT2b N0 M1 RCC, Fuhrman grade II, with pancreatic tail metastasis; both, primary and metastatic lesions had the same histological characteristics with negative surgical margins. After 9 months patient had no evidence of disease recurrence at radiological studies.

conclusionsThe rationale for surgical removal of disseminated tumor, followed by immunotherapy, includes improving prognosis and enhancing the potential of an immune-mediated response to systemic treatment. A spleen-sparing procedure can adequately preserve post-operative immunologic capabilities. In our experience, the correct assessment of pre-operative imaging data and surgeon skills in robotic surgery seem to play a key role in the success of these procedures. Robotic surgery seems to enhance the possibility to control multiple vessels encountered during dissection. Such a conservative approach may be helpful in future research aimed at uncovering biological features, and also leading to better targeted preventive interventions and more individualized and effective treatments.

Indexed as

AgedCarcinoma, Renal CellFemaleHumansKidney NeoplasmsNephrectomyOperative TimePancreatectomyPancreatic NeoplasmsPrognosisRobotic Surgical ProceduresTreatment OutcomeDistal atypical pancreasectomyKidney cancerMetastasectomyRobot-assisted surgerySpleen-preservation

Identifiers

PMID29895293
PMCPMC5998557
OpenAlexW2808624775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.